| Literature DB >> 32375812 |
Chunbo Chen1,2, Ying Qin1,2, Kun Qian1,2,3, Hongxia Shao1,2,3, Jianqiang Ye4,5,6, Aijian Qin7,8,9.
Abstract
BACKGROUND: Infectious bursal disease (IBD) is a highly contagious infectious disease that causes severe immunosuppression and damage to the bursa of Fabricius in chickens. Several proteins involved in IBD virus (IBDV) infection, such as surface immunoglobulin M, integrin, annexin A2 and chicken heat shock protein 90, have been identified. However, the main protein that plays key roles in virus infection has not yet been confirmed.Entities:
Keywords: DF-1 cells; HSC70; Infectious bursal disease virus; Virus infection
Mesh:
Substances:
Year: 2020 PMID: 32375812 PMCID: PMC7201719 DOI: 10.1186/s12985-020-01333-x
Source DB: PubMed Journal: Virol J ISSN: 1743-422X Impact factor: 4.099
Fig. 1pcDNA-VP2-DF-1 cell proteins were subjected to coimmunoprecipitation and silver staining. Lane 1, Some protein bands were coimmunoprecipitated with monoclonal antibody 2H11; lane 2, Few protein bands were coimmunoprecipitated with normal control IgG; lane 3, protein marker
Fig. 2MALDI-TOF analysis result of proteins bound by IBDV VP2 using coimmunoprecipitation. The mass-charge ratios of the polypeptide fragments were determined using a full scan method. The main mass peaks were observed
Proteins identified by mass spectrometry
| Protein group | Protein number | Protein name | Accession no. | Coverage percent | Unique peptide count |
|---|---|---|---|---|---|
| Cytoskeletal- associated proteins | 1 | Myosin-9 | sp | 31.55% | 122 |
| 2 | Vimentin | tr | 68.48% | 154 | |
| 3 | Nonmuscle myosin heavy chain | tr | 16.80% | 49 | |
| 4 | Actin, cytoplasmic type 5 | sp | 46.54% | 30 | |
| 5 | Actin, aortic smooth muscle | sp | 24.40% | 12 | |
| 6 | Alpha tropomyosin of brain | tr | 20.76% | 20 | |
| 7 | Paranemin | tr | 6.18% | 14 | |
| 8 | Beta-tropomyosin | tr | 21.77% | 12 | |
| 9 | Unconventional myosin-Ic | sp | 4.96% | 9 | |
| 10 | Ovalbumin | sp | 13.73% | 10 | |
| 11 | Myosin-11 | sp | 2.09% | 7 | |
| 12 | heat stable cytoskeletal protein | tr | 42.31% | 3 | |
| 13 | Filamin | tr | 1.72% | 5 | |
| 14 | Unconventional myosin-VI | sp | 3.06% | 3 | |
| 15 | F-actin-capping protein | sp | 14.08% | 2 | |
| 16 | Tubulin alpha-1 | sp | 8.01% | 2 | |
| 17 | EF hand-containing protein 1 | tr | 7.14% | 5 | |
| 18 | protein epsilon | sp | 7.45% | 2 | |
| 19 | FERM, RhoGEF and pleckstrin domain-containing protein 1 | sp | 1.72% | 1 | |
| 20 | Spectrin alpha chain, nonerythrocytic 1 | sp | 0.69% | 1 | |
| 21 | Histone | sp | 23.53% | 1 | |
| 22 | Coronin | tr | 6.12% | 1 | |
| Enzyme-related proteins | 1 | Serine/threonine-protein phosphatase | sp | 10.70% | 6 |
| 2 | DNA ligase | tr | 2.22% | 2 | |
| 3 | Protein phosphatase 1 regulatory | sp | 1.00% | 2 | |
| 4 | ATP synthase subunit alpha | tr | 3.98% | 2 | |
| 5 | GMP reductase | tr | 4.70% | 1 | |
| 6 | Isoleucine-tRNA ligase, mitochondrial | sp | 1.70% | 1 | |
| 7 | Phosphatidylinositol 4-phosphate 5-kinase type-1 | sp | 1.85% | 1 | |
| 8 | Protein phosphatase 1 regulatory subunit 21 | sp | 1.16% | 1 | |
| 9 | Nonspecific serine/threonine protein kinase | tr | 0.70% | 1 | |
| 10 | Succinate dehydrogenase, mitochondrial | sp | 4.83% | 1 | |
| 11 | Phosphoinositide phospholipase C | tr | 0.65% | 1 | |
| 12 | Protein-tyrosine-phosphatase | tr | 1.84% | 1 | |
| 13 | Alpha-enolase | sp | 5.07% | 1 | |
| Cell regulatory-related proteins | 1 | Heat shock cognate 71 kDa protein | sp | 7.89% | 6 |
| 2 | Elongation factor 1 | sp | 4.98% | 4 | |
| 3 | Stress-70 protein, mitochondrial | sp | 5.19% | 3 | |
| 4 | Protocadherin-15 | sp | 0.74% | 2 | |
| 5 | Tumor suppressor BRCA2 | tr | 0.53% | 2 | |
| 6 | 60S ribosomal protein L6 | tr | 5.03% | 2 | |
| 7 | Neuronal acetylcholine receptor | sp | 3.08% | 1 | |
| 8 | Elongator complex protein 3 | sp | 3.30% | 1 | |
| 9 | Monocarboxylate transporter 4 | sp | 2.11% | 1 | |
| 10 | Lamin-B1 | tr | 2.00% | 1 |
Fig. 3IBDV infection in DF-1 cells blocked by anti-HSC70 antibody at different concentrations. a: IFA results showed DF-1 cells pretreated with the antibody to HSC70. The higher concentration of the antibody, the blocking effect better. Normal IgG: same isotype of IgG for control. Positive control: DF-1 cells infected with IBDV. b: The viral titers in DF-1 cells after pretreatment with the anti-HSC70 antibody at different concentrations. c: Western blot results of the protein expression level of VP2 in DF-1 cells treated with/without antibody to HSC70. Lane 1–3: the protein expression levels treated with anti-HSC70 antibody at concentration of 25 μg/mL, 12.5 μg/mL and 6.25 μg/mL respectively; lane 4: normal IgG as control; lane 5: DF-1 cells infected with IBDV as positive control; GAPDH: the internal reference control. The relative expression level of VP2 was quantified by normalizing GAPDH control. After data analysis, the values of VP2/GAPDH are 0, 0.537, 1.425, 3.329, and 3.345 from left to right
Fig. 4Inhibitory assay of the inhibitor VER155008 for IBDV replication in DF-1 cells. a: Morphological changes in DF-1 cells treated with/without the inhibitor VER155008 at different time points. b: Western blot results of the VP2 protein in DF-1 cells treated with the inhibitor VER155008 at different time points. GAPDH: internal reference control in each time point
The viral titers in DF-1 cells treated with the inhibitor (VER155008)
| Viral titer (log10TCID50/mL) | |||
|---|---|---|---|
| Time | 24 h | 48 h | 72 h |
| Treated | 0 | 0 | 0 |
| Untreated (control) | 3.15 | 5.94 | 7.23 |
Fig. 5The inhibitory effects on IBDV in DF-1 cells treated with the inhibitor (VER155008) at different concentrations. a: The CPE of IBDV in DF-1 cells preincubated with the inhibitor (VER155008) at different concentrations. Positive control: DF-1 cells infected with 0.1 MOI of IBDV. b: TCID50 titration of IBDV in DF-1 cells pretreated with different concentrations of the inhibitor. c: Western blot analysis of IBDV VP2 protein expression in DF-1 cells pretreated with different concentrations of the inhibitor. Lanes 1–4: 5 μM, 0.5 μM, 0.05 μM, and 0.005 μM of VER155008 pretreatment respectively; lane 5: Positive control (DF-1 cells infected with 0.1 MOI of IBDV)